Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.47 |
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792506 | 0.87 | MAOB (0.47) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL792822 | 0.87 | PRKCA (0.44) | PRKCAMMP12 | |
| SCHEMBL772182 | 0.87 | PRKCA (0.51) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL792413 | 0.85 | MAOB (0.44) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL792918 | 0.85 | NR1I2 (0.36) | PRKCAMMP12 | |
| SCHEMBL10283177 | 0.84 | MAOB (0.44) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL772494 | 0.84 | PRKCA (0.45) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL772138 | 0.81 | PRKCA (0.51) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL772345 | 0.79 | MAOB (0.46) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL792770 | 0.78 | MAOB (0.44) | MAOBGRM5NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | MAOB 2789/4885GRM5 4000/4885NPC1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.